Shu Ming, Fan Zhiqiang, Huang Bin, Wang Chunjiang
Department of Hepatopancreatobiliary Surgery, Ningbo No.2 Hospital, Ningbo, 315010, Zhejiang, China.
Department of Pharmacy, The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China.
Invest New Drugs. 2025 Apr 30. doi: 10.1007/s10637-025-01536-5.
To explore the clinical features of pembrolizumab induced psoriasis to provide reference for the optimal treatment of immune checkpoint inhibitor-induced psoriasis. Clinical reports of pembrolizumab induced psoriasis were collected by searching the database until January 31, 2025. The clinical data extracted from the collected articles were retrospectively analyzed. A total of 42 patients were included, 76.2% male, with a median age of 69 years (range 28, 83). These patients included 21 (50.0%) patients with new-onset psoriasis and 21 (50.0%) patients with pre-existing psoriasis. The duration of onset of psoriasis was 8 weeks (range 0.4, 108), and the duration of onset of new psoriasis was longer than that of preexisting psoriasis (9 weeks vs. 7.2 weeks). Plaque psoriasis (38.1%) and psoriatis vulgaris (33.3%) were the most commonly reported phenotypes. After discontinuation or continuation of medication, 90.5% of patients experienced partial or complete improvement of skin symptoms after receiving topical, biologics, and oral systemic treatments. Pembrolizumab induced psoriasis can lead to various types of psoriasis, mainly in elderly and male patients. The pathogenesis and optimal treatment of Pembrolizumab in psoriasis require further investigation.
探讨帕博利珠单抗诱导的银屑病的临床特征，为免疫检查点抑制剂诱导的银屑病的最佳治疗提供参考。通过检索数据库收集截至2025年1月31日帕博利珠单抗诱导银屑病的临床报告。对从收集的文章中提取的临床数据进行回顾性分析。共纳入42例患者，男性占76.2%，中位年龄69岁（范围28至83岁）。这些患者包括21例（50.0%）新发银屑病患者和21例（50.0%）既往有银屑病患者。银屑病发病时长为8周（范围0.4至108周），新发银屑病的发病时长比既往有银屑病的患者更长（9周对7.2周）。斑块状银屑病（38.1%）和寻常型银屑病（33.3%）是最常报告的表型。停药或继续用药后，90.5%的患者在接受局部、生物制剂和口服全身治疗后皮肤症状部分或完全改善。帕博利珠单抗诱导的银屑病可导致多种类型的银屑病，主要发生在老年男性患者中。帕博利珠单抗在银屑病中的发病机制和最佳治疗方法需要进一步研究。
